Find Academic Supervisors

Edoardo Sozzi is a Visiting Research Fellow and PhD student at Lund University's Faculty of Medicine, specializing in the Developmental and Regenerative Neurobiology group under Prof. Malin Parmar. He earned a BSc in Biotechnology (2018) and a dual MSc in Neuroscience (2020) from the University of Pisa and Scuola Normale Superiore, Italy. His research focuses on the development, functionality, and diversity of human dopaminergic neurons using 3D cell culture systems like brain organoids and xenograft models, with heavy reliance on single-cell RNA sequencing. His work intersects neuroscience, developmental biology, and regenerative medicine, targeting neurodegenerative disorders such as Parkinson's disease. Key publication trends include innovations in organoid technology , single-cell transcriptomics , and WNT signaling modulation . He has contributed to 11 scientific outputs , including a 2025 doctoral thesis, peer-reviewed articles in Nature Methods and Development , and a 2023 Horizon Europe grant (OpenMIND project) for opto-electronic neural modeling in neurodegenerative diseases. Sozzi actively participates in academic events, organizing conferences like Neuroscience Day 2024 and UniStem Day 2024 , and serves as a presenter in multidisciplinary initiatives (MultiPark). His work aligns with UN Sustainable Development Goals for Medical and Health Sciences and Neurosciences .

• Neuroscience
• Neurobiology
• Stem Cell Research
• +6 more

Jan Johansson is a Professor at the Department of Medicine, Huddinge, Karolinska Institutet, specializing in protein biochemistry and translational research. His work focuses on developing novel medical treatments using molecular chaperones for neurodegenerative diseases like Alzheimer’s, spider silk-based biomaterials, and synthetic surfactants for respiratory disorders. He earned his Medical Degree (1990) and PhD (1991) from Karolinska Institutet, with research spanning protein aggregation mechanisms, drug development, and biomedical applications. Education: MD from Karolinska Institutet (1990), PhD in Biochemistry (1991). Research Interests: Molecular chaperones, protein aggregation, Alzheimer’s disease, spider silk biomaterials, synthetic surfactants. Grants: Multiple projects funded by the Swedish Research Council, VINNOVA, and others, including studies on BRICHOS chaperone mechanisms and biomimetic silk production. His lab explores chaperones’ potential to cross the blood-brain barrier, combat amyloid toxicity, and deliver therapeutic agents. Notable contributions include designing synthetic surfactants for neonatal respiratory distress syndrome and elucidating spider silk’s structural basis for toughness. Collaborations with industries and academic institutions drive translational research toward clinical applications.

• Biochemistry
• Cell and Molecular Biology
• Neurodegenerative Diseases
• +3 more

Per Svenningsson is a Professor of Neurology and Senior Physician at the Department of Clinical Neuroscience, Karolinska Institutet, and leads the Neuropharmacology research group focusing on movement disorders, particularly Parkinson's disease. He holds appointments at Karolinska University Hospital and is affiliated with the Biopark cohort and multiple collaborative initiatives. His research integrates clinical, translational, and experimental approaches to understand disease mechanisms and develop biomarkers. Education: MD (1996) and PhD (1998) from Karolinska Institutet. Research expertise spans neuropharmacology, neurodegeneration, and psychiatric comorbidities like depression. He leads projects on Parkinson's non-motor symptoms, biomarker development, and clinical trials for disease-modifying therapies. Research interests include: Pathophysiology of Parkinson's disease Biomarkers and early diagnosis Neurochemical changes in L-DOPA-induced dyskinesia Role of glial cells and lipid homeostasis Novel drug targets using mass spectrometry imaging Key publications focus on parkinsonism models, computational memory capacity, and molecular mechanisms in depression. His work has been supported by grants from the Swedish Research Council, Wallenberg Foundation, and international initiatives like ASAP for Parkinson's research. Advising includes supervision of PhD students Behzad Iravani and Lovisa Brodin. Collaborations involve teams across neurology, psychiatry, and bioinformatics, emphasizing multidisciplinary approaches to neurodegenerative diseases. Labs/Teams: Neuropharmacology - Movement Disorders group at Karolinska Institutet, contributing to the Biopark cohort and international clinical trials (e.g., Montelukast for Parkinson's neuroinflammation).

• Neurology
• Neurosciences
• Parkinson's Disease
• +4 more

Kristoffer N T Månsson serves as Associate Professor and Principal Investigator at Karolinska Institutet's Department of Clinical Neuroscience, leading the Månsson Lab with active collaborations across Stockholm University, Uppsala University, Dartmouth College, and Babeș-Bolyai University. His research program integrates neuroimaging, computational psychiatry, and clinical interventions to identify neural biomarkers for psychiatric treatment response. Research focuses on neural variability as a predictor of treatment outcomes in anxiety and depression, with particular emphasis on rapid brain plasticity during cognitive behavioral therapy. His team employs multimodal approaches including fMRI, structural MRI, and peripheral biomarker analysis to investigate moment-to-moment neural dynamics in psychiatric disorders. Key projects include the TREVAR study on neural variability in anxiety/depression and EU-funded research on adolescent mental health in Romania. Current funding sources include the Swedish Research Council (6 MSEK for placebo responsiveness studies), European Union (€1.3M for child/adolescent anxiety research), CIMED, and the Swedish Brain Foundation. His work demonstrates consistent translational impact, with multiple publications in Biological Psychiatry and Cerebral Cortex receiving significant media coverage in Scientific American and Swedish outlets. Somerfeld-Ziskind Research Award Honorable Mention (2023) StratNeuro Retreat Best Clinical/Translational Poster (2022) Lab members include postdocs specializing in computational neuroscience (Tsikonofilos, Zika), research engineers (Manzouri), and PhD students from international institutions. The team actively collaborates with leading researchers including Tor Wager (Dartmouth), Tomas Furmark (Uppsala), and Mats Lekander (Stockholm University) on projects spanning neural plasticity, biomarker validation, and treatment optimization.

• Neuroscience
• Psychiatry
• Neuroimaging
• +3 more

Björn Granseth is an Associate Professor at Linköping University's Department of Biomedical and Clinical Sciences (BKV), affiliated with the Faculty of Medicine and Health Sciences. He holds the title of Docent and is part of the Division of Cell and Neurobiology. His research focuses on neural circuits, synaptic plasticity, and neurotransmitter modulation, particularly in corticothalamic communication and motivational processes. Granseth is affiliated with the Wallenberg Centre for Molecular Medicine (WCMM) and the Center for Social and Affective Neuroscience (CSAN). His work explores cholinergic and noradrenergic modulation of synaptic inputs, VGluT1's role in visual attention, and striatal melanocortin receptors' influence on motivational valence. Key techniques include genetic mouse models (Ntsr1-Cre GN220) and in vitro electrophysiological studies. Granseth collaborates on projects involving neuropharmacology (e.g., Sigma-2 receptor agonists) and developmental biology (Hedgehog signaling in Drosophila). Recent articles highlight contributions to understanding corticothalamic synapses, synaptic plasticity deficits in VGluT1-deficient mice, and the neurobiology of reward circuits. His research bridges basic neuroscience with clinical implications, particularly in neurological disorders.

• Neuroscience
• Neural Circuits
• Synaptic Plasticity
• +3 more

Silvia Castany Quintana is a Principal Research Engineer and Postdoctoral Researcher at the Center for Social and Affective Neuroscience (CSAN), affiliated with Linköping University's Faculty of Medicine and Health Sciences. She is a core member of The Engblom Lab, which investigates neuroimmune mechanisms underlying aversive affective states and depressive symptoms in inflammatory diseases and major depression. Her research focuses on neuroimmunology, pain management, and the interplay between immune responses and neurological disorders. Key areas include microglial activation, prostaglandin pathways, and neuroinflammation's role in mood disorders. She has contributed to studies on social transmission of inflammation, chronic pain mechanisms, and sigma-1 receptor pharmacology. Collaborations involve multidisciplinary teams exploring neuroimmune interactions in health and disease. Her work integrates behavioral, molecular, and cellular neuroscience methodologies. Labs/Teams: Member of The Engblom Lab (BKV Department) and CSAN. Affiliated with Department of Biomedical and Clinical Sciences at Linköping University.

• Neuroimmunology
• Neuroscience
• Immunology
• +3 more

Irene Perini is a Principal Research Engineer and Docent at Linköping University, affiliated with the Center for Social and Affective Neuroscience (CSAN) and the Department of Biomedical and Clinical Sciences (BKV). Her research focuses on social neuroscience, addiction medicine, and neuropsychology, employing methods like functional MRI (fMRI), transcranial magnetic stimulation (TMS), and behavioral analysis. Education highlights include a PhD in Medicine from the University of Gothenburg (2013), an MA in Neuropsychology from the University of Bologna (2008), and a BA in Psychology from the University of Parma (2006). She has held roles including postdoctoral researcher (2014–2015) and principal research engineer at CSAN since 2015. Notable awards include the ERNI-HSF Exchange Grant (2011). Her work explores brain mechanisms underlying social interactions, addiction, and mental health disorders. Recent studies include investigating negative social bias in adolescents with nonsuicidal self-injury and the role of the cannabinoid system in addiction resilience. She has led randomized controlled trials on TMS for alcohol dependence and contributed to methodological advancements in fMRI drug cue reactivity studies. Key collaborations involve the Heilig Translational Psychiatry Lab and the Department of Clinical and Experimental Medicine. Current research themes integrate neuroimaging, pharmacology, and behavioral science to address stress coping mechanisms and neural pathways in psychiatric disorders.

• Social Neuroscience
• Addiction Medicine
• Neuroimaging
• +5 more

Magnus Schou is an Adjunct Professor of Medical Radiochemistry at the Department of Clinical Neuroscience , Karolinska Institutet. His work focuses on molecular brain imaging of neurodegenerative disorders within the Andrea Varrone's research group. Current position: Adjunct Professor (2022-2026) Education: Ph.D. (2006), Docent (2020) in Clinical Neuroscience Research Interests: Magnus Schou specializes in PET radioligand development for neurodegenerative diseases. His work involves: Designing novel PET tracers for serotonin, dopamine, and norepinephrine transporters Optimizing radiolabeling techniques using carbon-11 and fluorine-18 Evaluating radioligands in non-human primates and humans Investigating brain exposure of CNS drugs Article Trends: His recent publications emphasize innovations in PET radioligand synthesis , including transition-metal-free labeling methods, microfluidic radiosynthesis, and imaging of neurodegenerative pathology (amyloid-β, alpha-synuclein). Key areas include neuropharmacology, isotope chemistry, and clinical validation.

• Neurosciences
• Medical Radiochemistry
• Molecular Imaging
• +2 more

Mia Ericson is a Professor at the Section of Psychiatry and Neurochemistry and Vice Dean of the Sahlgrenska Academy, University of Gothenburg. Her research group, 'Addiction Medicine', investigates neurochemical mechanisms of substance dependence using rodent models. Her work centers on dopamine, glycine, and taurine dynamics in addiction, with emphases on alcohol and nicotine effects on striatal circuitry. Key research areas include neuroadaptations during withdrawal, astrocyte-neuron interactions, and pharmacological interventions targeting glutamate/GABA systems. Recent publications (2022-2025) demonstrate a focus on: Neuroimmune interactions in opioid/alcohol dependence Sex-specific neuroadaptations in nicotine/amphetamine withdrawal Glycine transporter inhibition as a therapeutic strategy Astrocytic modulation of synaptic plasticity

• Addiction Medicine
• Neurochemistry
• Behavioral Neuroscience
• +2 more

Merab Kokaia is a Professor in Neurology at Lund University , Principal Investigator at the Epilepsy Center, and Project Manager of the Experimental Epilepsy Group. His research focuses on the role of neuropeptides and neurotrophic factors in synaptic transmission and epileptogenesis, utilizing animal models and advanced techniques like optogenetics. Key research areas: Neuroscience Neurology Epilepsy Synaptic transmission Optogenetics Recent article trends (15 most recent) highlight his work on: Molecular mechanisms of seizure suppression Gene therapy approaches for epilepsy Optogenetic and chemogenetic interventions Hippocampal dysfunction in epilepsy Translational animal models Infrastructure & projects include leadership roles in the Epilepsy Center and involvement in nanoscience initiatives like NanoLund . He supervises PhD students and collaborates widely in European epilepsy research networks.

• Neuroscience
• Neurology
• Epilepsy
• +5 more

Jenny Wickham is a PhD postdoctoral researcher and research engineer at the Brain Repair and Imaging in Neural Systems (BRAINS) Research Group at Lund University's Faculty of Medicine , with affiliations to the national StemTherapy initiative. Her work bridges neuroscience, neurology, and regenerative medicine through optogenetics and brain tissue research. Her research focuses on Epilepsy mechanisms and translational therapies Optogenetic circuit modulation Interneuron dynamics in seizure networks Neuroinflammatory interventions Ex vivo brain slice preservation Neuropeptide-based treatments Across her 2023-2018 publications, key trends include optogenetic epilepsy control , interneuron-targeted interventions , and translational approaches combining neuroscience and regenerative strategies for drug-resistant epilepsy. As conference chair for Neuroscience Day 2024 , she contributes to academic event organization within her field.

• Neuroscience
• Neurology
• Epilepsy
• +5 more

Marianne Schultzberg is a Professor of Clinical Neuroscience at the Department of Neurobiology, Care Sciences and Society, Karolinska Institutet. She has been affiliated since 2005 and leads a research group focusing on neuroinflammation in Alzheimer’s disease, particularly investigating cytokines like interleukin-1 (IL-1) and pro-resolving mediators. Her work combines cellular and animal models with clinical collaborations to identify novel treatments. Education: BSc in biochemistry (1974) PhD in neuropeptides (1980) Postdoc at University of Liverpool (1980–1981) Docent (associate professor) in 1983 Research Interests: Chronic neuroinflammation in Alzheimer’s, cytokine signaling, microglial activation, and translational approaches to neurodegenerative therapies. Her group studies IL-1 receptor modulation, pro-resolving lipid mediators, and β-amyloid clearance mechanisms. Grants & Awards: Supported by the Swedish Research Council, Stockholm County Council, and others. Notable grants include Molecular Detail of Resolution of Inflammation in Alzheimer’s (2024–2026). Labs/Teams: Neuroinflammation in Alzheimer Disease research group, collaborating on translational studies linking basic science to clinical applications.

• Neurodegenerative Diseases
• Alzheimer's Disease
• Neuroinflammation
• +3 more

Henrik Green serves as Deputy Head of Department and Professor in forensic sciences at Linköping University's Department of Biomedical and Clinical Sciences, Faculty of Medicine and Health Sciences. He also holds a position as Researcher/Molecular Biologist in Engineering and Genomics at the Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine, Linköping. His research spans three primary tracks: Genetic variation affecting drug response and side effects in cancer treatment Pharmacology and toxicology of new psychoactive substances (internet drugs) Forensic applications of genetics, including post-mortem metabolomics and AI for solving murders Green's work focuses on identifying predictive biomarkers for drug metabolism and effects, with recent publications examining synthetic cannabinoids, pharmacogenomics in pediatric oncology, and cardiac genetics. His research group has developed tools to predict nerve damage from taxane-based cancer treatments and methods for rapid narcotics classification of new psychoactive substances. He leads the Strategic Research Area in Forensic Sciences, a joint venture between the National Board of Forensic Medicine and Linköping University, and is part of the Cancer research network and SciLifeLab Linköping infrastructure. His team recently received SEK 13 million from the Swedish Research Council to develop AI methodologies for crime solving through detailed chemical analyses. Green has developed rapid methods for measuring the effects of new psychoactive substances, contributing directly to narcotics classification efforts. His work on fentanyl analogues helped remove these dangerous substances from the market, preventing numerous deaths. He emphasizes the critical race against time when new designer drugs emerge, comparing consumption of unknown substances to 'playing Russian roulette.'

• Pharmacogenetics
• Toxicology
• Forensic Sciences
• +5 more

My Hedhammar is Professor in Biotechnology at KTH Royal Institute of Technology developing innovative methods for tissue engineering using recombinant spider silk. Her laboratory creates three-dimensional tissue models that mimic natural cellular environments. Research focuses on spider silk-derived biomaterials that serve as scaffolds for cell cultivation, enabling the creation of complex tissue structures including vascularized models. Applications include cancer tumor modeling and diabetes treatment through pancreatic islet transplantation. Recent publications (2023-2025) demonstrate advancements in silk functionalization, cryopreservation techniques, and disease-specific models. Work consistently bridges biomaterial science with clinical applications in regenerative medicine and drug development.

• Tissue Engineering
• Biomaterials
• Spider Silk Applications
• +3 more

Marja-Liisa Dahl is a Professor and Senior Physician at the Department of Laboratory Medicine, Karolinska Institutet in Stockholm, Sweden. She holds a Docent degree from Karolinska Institutet since 1992 and has been actively employed in her current role since 2012. Her research focuses on clinical pharmacology, with a strong emphasis on pharmacogenetics, drug metabolism, and the clinical implications of genetic variability in drug response. Her work spans areas such as HIV therapy optimization in pediatric populations, pharmacokinetic studies of medications like methylphenidate and methadone, and the social and clinical impacts of anabolic steroids. She also investigates drug interactions and safety in elderly patients with polypharmacy. Her research integrates quantitative methods, epidemiological studies, and qualitative insights to address real-world clinical challenges. Key themes in her publications include: Genetic determinants of drug efficacy and toxicity (e.g., CYP2B6, CYP2C19 variants) Pharmacovigilance in psychiatric and substance use disorders Development of clinical decision support systems Gender-specific effects of doping agents While no specific scientific awards are listed, her extensive publication record reflects her leadership in clinical pharmacology research. Her work contributes to improving drug safety and personalized medicine approaches in global healthcare settings.

• Clinical Laboratory Medicine
• Pharmacology and Toxicology
• Psychiatry
• +3 more